Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 14/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 6/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | WRN | Q14191 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308441 | 0.86 | MGLL (0.45) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL43497 | 0.85 | MGLL (0.48) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL4309956 | 0.83 | MGLL (0.52) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL4309970 | 0.83 | MGLL (0.52) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL4301460 | 0.83 | MGLL (0.52) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL4302889 | 0.83 | MGLL (0.52) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL4306818 | 0.83 | MGLL (0.52) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL7044109 | 0.83 | MGLL (0.52) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL17065231 | 0.83 | MGLL (0.52) | MGLLALDH1A1BLMLMNAMAPT | |
| SCHEMBL4304987 | 0.83 | MGLL (0.52) | MGLLALDH1A1BLMLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170358509-A1 | PROCESS OF ENCAPSULATING ELECTRONIC COMPONENTS | VALEO EQUIPEMENTS ELECTRIQUES MOTEUR (FR) | 2017-12-14 | — | — | US | claimed |
| EP-3227908-A1 | PROCESS FOR ENCAPSULATING ELECTRONIC COMPONENTS | Valeo Equipements Electriques Moteur (FR) | 2017-10-11 | — | — | EP | claimed |
| CN-102827272-A | Folate coupling antibody drug and its preparation method and use | WUHAN HUAYAO BIOLOG PHARMACEUTICAL CO LTD | 2012-12-19 | — | — | CN | claimed |
| CN-102199585-B | Preparation method of recombinant staphylokinase dimer and site-specific modificaton of polyethylene glycol | INST PROCESS ENG CAS | 2012-08-22 | — | — | CN | claimed |
| CN-102199585-A | Preparation method of recombinant staphylokinase dimer and site-specific modificaton of polyethylene glycol | INST PROCESS ENG CAS | 2011-09-28 | — | — | CN | claimed |
| US-20260126453-A1 | Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof | THE BINDING SITE GROUP LTD (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4675278-A2 | ASSAY FOR PLASMA CELL ASSOCIATED DISEASE | The Binding Site Group Limited (GB) | 2026-01-07 | — | — | EP | disclosed |
| US-12461108-B2 | Mass spectrometry kit including a cross-linked antibody or fragment thereof | THE BINDING SITE GROUP LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| US-20230391851-A1 | ANTIBODIES | THE BINDING SITE GROUP LIMITED (GB) | 2023-12-07 | — | — | US | disclosed |
| WO-2023131270-A1 | NOVEL INTERLEUKIN-2 POLYPEPTIDES | CURE GENETICS, CO., LIMITED (CN) | 2023-07-13 | — | — | WO | disclosed |
| US-20230184782-A1 | MASS SPECTROMETRY CONTROLS | THE BINDING SITE GROUP LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
| EP-4168583-A2 | METHOD OF CHARACTERISING A POLYNUCLEOTIDE MOVING THROUGH A NANOPORE | Oxford Nanopore Technologies plc (GB) | 2023-04-26 | — | — | EP | disclosed |
| EP-2440568-A1 | CROSS-LINKING OF SUPEROXIDE DISMUTASE MONOMERS | Brandeis University (US) | 2012-04-18 | — | — | EP | disclosed |
| CN-102199585-A | Preparation method of recombinant staphylokinase dimer and site-specific modificaton of polyethylene glycol | INST PROCESS ENG CAS | 2011-09-28 | — | — | CN | disclosed |
| WO-2011106086-A1 | PEGYLATED ALBUMIN POLYMERS AND USES THEREOF | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-09-01 | — | — | WO | disclosed |
| WO-2010141613-A1 | CROSS-LINKING OF SUPEROXIDE DISMUTASE MONOMERS | BRANDEIS UNIVERSITY (US) | 2010-12-09 | — | — | WO | disclosed |
| EP-1070119-A2 | IMMOBILIZED NUCLEASE FROM SERRATIA MARCESCENS | MERCK PATENT GmbH (DE) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999050397-A2 | IMMOBILIZED NUCLEASE FROM SERRATIA MARCESCENS | MERCK PATENT GMBH (DE) | 1999-10-07 | — | — | WO | disclosed |
| EP-0880785-A1 | PROCESS FOR IMPREGNATING ELECTRICALLY CONDUCTING SUBSTRATES | Dr. Beck & Co. Aktiengesellschaft (DE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997018567-A1 | PROCESS FOR IMPREGNATING ELECTRICALLY CONDUCTING SUBSTRATES | DR. BECK & CO. AG (DE) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260126453-A1 | Mass Spectrometry Kit Including a Cross-linked Antibody or Fragment Thereof | IGLV6-57, IGSF11, FCGR3B | MGLL 3531/4885ALDH1A1 2401/4885BLM 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.